BIM-IOL System

Primary open-angle glaucoma is a chronic, progressive optic neuropathy with an open anterior chamber angle and no secondary cause of IOP elevation. Ocular hypertension is a consistently elevated IOP, in the United States usually greater than 21 mmHg, without glaucomatous damage. IOP is the only known modifiable risk factor. A 2014 meta-analysis estimated a global glaucoma prevalence of 3.54% in people aged 40 to 80 years, or 76.0 million people in 2020, projected to reach 111.8 million in 2040; a 2026 meta-analysis estimated a global open-angle glaucoma prevalence of 2.8% (80.5 million people aged 40 years or older) in 2024, projected to reach 3.5% (186.6 million) by 2060. In the United States, an estimated 4.22 million people were living with glaucoma in 2022 (2.56% of people aged 40 years or older), 1.49 million with vision-affecting glaucoma, with a prevalence of 3.15% in Black adults compared with 1.42% in White adults. Prevalent POAG was identified in 5.5% to 6.2% of Medicare fee-for-service beneficiaries from 2017 to 2021. The prevalence of ocular hypertension is 4.5% in non-Hispanic White and 3.5% in Latino US adults aged 40 years or older.

The sources disagree on several burden estimates because of differences in scope and case definition. Global counts for 2020 are 76.0 million for all glaucoma types in one meta-analysis and 52.68 million for POAG in the AAO guideline, and a 2026 meta-analysis reports 80.5 million with open-angle glaucoma in 2024. US prevalence was 2.1% (2.9 million people aged 40 years or older) in NHANES 2005 to 2008 and 2.56% (4.22 million, a count that includes adults aged 18 years or older) in the 2022 CDC surveillance estimate. The undiagnosed share was reported as over half of participants with glaucoma in one NHANES analysis and as 78% in another analysis of the same survey cycles.

Untreated disease progresses. In the Ocular Hypertension Treatment Study (1,636 participants), the 5-year cumulative probability of POAG was 4.4% with medication and 9.5% with observation (hazard ratio 0.40), and the 20-year cumulative incidence was 45.6%, although visual field loss occurred in 25.2%. In the Early Manifest Glaucoma Trial, progression occurred in 45% of treated and 62% of untreated participants over a median of 6 years, and progression risk decreased by about 10% with each mmHg of initial IOP reduction. Pressure control does not prevent loss in every eye: in the Advanced Glaucoma Intervention Study, 13.1% to 14.4% of eyes whose IOP was below 18 mmHg at every visit still lost four or more units of visual field. In a Swedish cohort of 592 treated patients, the cumulative incidence of bilateral blindness was 5.5% at 10 years and 13.5% at 20 years, and globally glaucoma accounted for 3.61 million blind people (8.39% of all blindness) in 2020. Glaucoma was associated with falls (hazard ratio 1.38) and fractures (hazard ratio 1.31) in England; the fully adjusted association with mortality was not significant (hazard ratio 1.13). In the OHTS 20-year follow-up, the vision-related quality of life score was 58.5 with bilateral visual field POAG compared with 72.5 without POAG.

Glaucoma and cataract frequently coexist: glaucoma was recorded in 22.1% of 82,246 Medicare fee-for-service cataract surgery claims, and the manufacturer estimates that about 1 million of about 5 million US cataract surgeries in 2025 were performed in patients with glaucoma or ocular hypertension. Glaucoma was associated with incremental annual US health care expenditures of $1,863.17 per patient ($9.2 billion nationally), direct costs ranged from $623 per year in early disease to $2,511 per year in end-stage disease with medications accounting for 24% to 61%, and Medicare spending on prostaglandin analogs increased from $733 million in 2013 to $1.09 billion in 2017.

No phase 3 results and no peer-reviewed randomized results are available for the BIM-IOL System. Efficacy evidence consists of one published nonrandomized first-in-human study with its observational extension, and sponsor-reported topline results from one randomized phase 1/2 trial.

In the first-in-human study (SGP-SPEC-001, extended as SGP-SPEC-004), a single surgeon in Honduras implanted systems containing 75, 150, or 300 μg of bimatoprost in 24 participants (8 per cohort), all with POAG and of Hispanic or Latino ethnicity; 23 were analyzed per protocol after exclusion of one participant with preexisting diabetic retinopathy. Mean post-washout baseline IOP was 25.1 ± 2.5 mmHg. At month 6, every study eye had an unmedicated IOP reduction of at least 20%. At month 36 (21 participants), mean IOP was 15.9 ± 2.8 mmHg, a mean reduction of 36.7 ± 9.4% (p < 0.0001); all 21 eyes maintained a reduction greater than 20%, 19 (90.5%) had IOP below 18 mmHg, and 20 (95.2%) were free of topical medication. IOP change did not differ among dose cohorts (p = 0.50 at month 36).

In the phase 1/2 trial (SGP-003, Tigris), 104 participants undergoing cataract surgery were randomized 2:1:1 to the 78 mcg system (51), the 39 mcg system (23), or a commercial monofocal IOL plus twice-daily timolol (30). At 3 months, mean IOP reductions at 8 a.m. were 37%, 36%, and 37%, and 49 of 50 (98%) and 22 of 23 (96%) participants in the 78 mcg and 39 mcg groups were free of topical IOP-lowering medication. At 12 months, mean IOP reductions were 34% (47 evaluable), 42% (21), and 35% (29); 48 of 49 (98%) and 22 of 23 (96%) participants in the 78 mcg and 39 mcg groups were medication free; and 72 of 72 (100%) evaluable BIM-IOL participants had BCDVA of 20/32 or better. No confidence intervals, p values, or noninferiority analyses have been published.

In the phase 1/2 trial, adverse event rates were 35.3% (78 mcg), 39.1% (39 mcg), and 33.3% (control) at 3 months and 41.2%, 43.5%, and 36.7% at 12 months, with no serious ocular adverse events; one participant (1 of 50, 2.0%) receiving the system reported allergic conjunctivitis, and mean endothelial cell density loss at 3 months was 14.9% with the system and 12.1% with control. In the first-in-human study through 36 months, the most common adverse events were dry eye (5 of 23, 21.7%), transient loss of 2 or more lines of BCDVA (3, 13.0%), and subconjunctival hemorrhage (2, 8.7%); conjunctival hyperemia occurred in 1 participant (4.3%). There were no implant-related serious adverse events, IOL dislocations, drug pad displacements, or explantations, and endothelial cell density decreased by 12.8% at month 12.

The sources disagree on several points. The phase 1/2 registry record lists an actual enrollment of 201, whereas all company disclosures report 104 randomized participants. The 12-month medication-free rate is reported by dose group as 98% and 96%, and as a pooled 97% in the Form 10-K and a trade-journal article. The 78 mcg IOP reduction decreased from 37% at 3 months to 34% at 12 months, which the Form 10-K describes as "sustained similar rates"; the 12-month IOP denominators (47, 21, and 29) differ from the medication-free denominators (49 and 23). For the first-in-human study, enrollment is 24 in the registry and publication and 23 in company materials; the month 36 IOP is reported as 15.9 ± 2.8 mmHg in the publication and Form 10-K and 15.9 ± 2.7 mmHg in a November 2025 company announcement; the month 18 IOP is 13.9 ± 2.2 mmHg (44.4% reduction) in the publication, 14.1 ± 2.6 mmHg in a trade report of the 2025 ASCRS presentation, and a 43.7% reduction in an AAO news report; and the registry describes the study as "controlled" with a masked outcomes assessor, whereas the publication reports no control group and states that neither participants nor investigators were masked. For the phase 3 trials, the registry lists the BCDVA co-primary endpoint at month 6, whereas the Form 10-K states 12 months, and the Form 10-K states that the trials were initiated in July 2025, whereas the registry start dates are October 15, 2025 (SGP-005, actual) and October 28, 2025 (SGP-006, estimated). A March 2026 company announcement describes the system as delivering "multiple years" of bimatoprost, whereas the Form 10-K and later announcements specify three years.

The registrational phase 3 trials SGP-005 (Rhine) and SGP-006 (Rhone) each plan to enroll approximately 400 participants and compare the 78 mcg system with a commercial monofocal IOL plus twice-daily timolol 0.5%, with follow-up through 36 months. The sponsor expects enrollment to complete in 2027 and 12-month data in 2028.

No price, cost-effectiveness analysis, budget impact model, or health technology assessment has been published for the BIM-IOL System, and no published cost-effectiveness or budget impact analysis of the approved intracameral implants (Durysta or iDose TR) was identified. The sponsor plans to submit a 505(b)(2) NDA in 2028.

The sponsor estimates a US total addressable market of approximately $13 billion, based on the estimated 1 million patients with glaucoma or ocular hypertension undergoing cataract surgery each year, the proportion of glaucoma that is open-angle, and the wholesale acquisition cost of iDose TR, which Glaukos set at $13,950 per implant in December 2023. The sponsor expects the system to be covered under Medicare Part B, billed first under a temporary J-code (J3490 or J3590) and then under a permanent product-specific J-code, and reimbursed at ASP plus 6%, as for Durysta (J7351) and iDose TR (J7355), and states that approximately 90% of US cataract surgeries are performed in ambulatory surgery centers. Medicare Part B payment limits for July to September 2026 were $213.756 per 1 mcg for J7351 and $196.746 per 1 mcg for J7355. The sources disagree on the procedure code: the May 2026 company announcement lists the approved add-on Category III CPT code as +X659T, whereas the August 2026 results announcement reports the code released on July 1, 2026 as +1090T, for use with cataract surgery codes such as 66984 and 66991.

The nearest published economic evaluations concern MIGS devices implanted during cataract surgery. A US Medicare model estimated incremental cost-utility ratios for the Hydrus microstent with cataract surgery, compared with cataract surgery alone, of USD 38,346.43 in mild and USD 42,895.38 in moderate glaucoma over 2 years; a 35-year US societal model found that Hydrus or iStent inject with cataract surgery dominated or was cost-effective compared with cataract surgery alone; and a 2-year budget impact model of the OMNI surgical system in a hypothetical US plan with 1 million Medicare-covered lives estimated a total cost decrease of $35,362. For the topical comparator class, Medicare spending on prostaglandin analogs was $1.09 billion in 2017, of which 86% was for branded products, and median Medicare Part D glaucoma medication spending was $403.81 per beneficiary from 2019 to 2023. Budget impact for the BIM-IOL System cannot be estimated from public data as of September 2026.

The BIM-IOL System is an investigational drug-device combination product in which two non-bioerodible silicone pads containing bimatoprost, a prostaglandin analog approved for topical use, are attached to a hydrophobic acrylic monofocal IOL and implanted in the capsular bag during cataract surgery, with a sponsor-stated design duration of three years. It is not approved in any jurisdiction. The sponsor expects regulation as a drug-led combination product and plans a 505(b)(2) NDA submission in 2028 after two phase 3 trials of the 78 mcg system in approximately 400 participants each.

Current evidence is limited to a nonrandomized first-in-human study in 23 analyzed participants and sponsor-reported topline results of a 104-participant phase 1/2 trial. In both, IOP reductions of 34% to 42% were reported, and 95% to 98% of evaluable participants were free of topical IOP-lowering medication at 12 to 36 months. In the phase 1/2 trial, the timolol control arm, which also underwent cataract surgery, had IOP reductions of 37% at 3 months and 35% at 12 months, so the reported difference is the avoidance of daily eye drops rather than greater IOP lowering. Cataract surgery alone lowered IOP by 16.5% in the OHTS observation group, and no study has compared the system with cataract surgery alone. The first-in-human cohort was single-site, unmasked, registered retrospectively, limited to prior prostaglandin analog responders, and tested doses (75, 150, and 300 μg) other than the phase 3 dose. No peer-reviewed phase 1/2 publication, variance estimates, or noninferiority analyses are available, and the sources differ on phase 1/2 enrollment, pooled versus dose-specific medication-free rates, and the timing of the phase 3 BCDVA co-primary endpoint.

In current practice, prostaglandin analogs are the usual initial medical therapy, with an expected IOP reduction of 25% to 33%, and laser trabeculoplasty is also a first-line option; NICE recommends 360° SLT first for newly diagnosed non-advanced chronic open-angle glaucoma. Adherence limits topical therapy: in a meta-analysis of 47 studies, 44% of patients on prostaglandin analogs were adherent at year 1, and persistence fell from 75% at month 6 to 31% at year 3. For patients with glaucoma and cataract whose IOP is at or near target, the European Glaucoma Society supports phacoemulsification alone or with MIGS. The two approved intracameral implants carry corneal endothelial cell warnings: Durysta is limited to a single implant per eye, and iDose TR may be readministered no more than once per year. The sources describe iDose TR durability differently: the 12-month publication of the GC-010 trial reports noninferiority to timolol at months 6, 9, and 12, while stating that the trial was not prospectively powered for the 6, 9, and 12-month evaluations and that the month 6 and 9 analyses were not prospectively defined, whereas the current iDose TR label states that noninferiority was not demonstrated over the 9 months after month 3. No direct comparison of the BIM-IOL System with topical therapy other than timolol, SLT, MIGS, or intracameral implants has been reported, and no price or budget impact estimate is available.